News | Image Guided Radiation Therapy (IGRT) | August 21, 2019

First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking

Advanced radiation therapy delivery system and intrafraction motion synchronization functionality enable precise, efficient treatment of lung cancer patient

First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking

August 21, 2019 — Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have treated the first cancer patient in the world using Accuray’s Radixact System with Synchrony motion tracking and correction technology. The patient was a 45-year-old man with lung cancer. With the addition of Synchrony, the Radixact System was able to track the lung tumor in real time as it moved with the patient's breathing and automatically adjust the radiation beam to keep it targeted on the tumor. This enabled the clinical team to deliver the maximum dose of radiation they felt necessary to destroy cancer cells, while minimizing the risk of damage to surrounding healthy tissues. The Radixact and CyberKnife systems both feature the Synchrony automated motion tracking and correction functionality.

The Froedtert & MCW Clinical Cancer Center, part of the Froedtert & MCW Cancer Network, is dedicated to using advanced treatment options to provide personalized treatments for every cancer patient. The clinical team installed the Synchrony upgrade because they wanted to further enhance the ability to deliver precise radiation treatment to their patients requiring this form of cancer therapy.

"The Froedtert & MCW Radiation Oncology team continues to identify and integrate technical advancements that have the potential to make radiation therapy treatment as precise, safe and effective as possible," said Christopher Schultz, M.D., FACR, FASTRO, Medical College of Wisconsin professor and chairman of the Department of Radiation Oncology with the Froedtert & MCW Cancer Network. "We have successfully treated the first patient, diagnosed with a lung tumor, using the Radixact System with Synchrony technology. With Synchrony, we were able to use a smaller treatment field when delivering radiation to the tumor as it moved. Without this technology, larger treatment fields would have been necessary to treat the entire path of the tumor movement. Alternatively, a much longer treatment time would have been needed to turn the radiation beam on and off as the tumor moved in and out of the specified treatment window. Overall, we believe that the addition of Synchrony to our Radixact System will expand treatment options for patients with mobile tumors, including those that are currently too large to treat without motion tracking."

"In our hospital network we've seen an increase in the use of hypofractionated stereotactic body radiation therapy as part of the cancer treatment, making it critically important that we are able to safely deliver the correct amount of dose precisely to the tumor, even to those that move such as tumors in thorax, abdomen and pelvis," said X. Allen Li, Ph.D., Medical College of Wisconsin professor and chief of medical physics at Froedtert Hospital. "Our comprehensive pre-treatment tests and the initial patient treatment showed us how well the Synchrony technology works in the real-world clinical practice. As a result, we now have an option for precisely and accurately delivering radiation to tumors as they move, which will expand the range of tumors we can confidently treat and the patients we can help."

Synchrony for the Radixact System is designed to correct for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement. The technology uses image guidance during treatment delivery to automatically adjust the movement of the radiation beam in synchronization with the movement of the tumor. The beams of radiation are delivered continuously throughout the treatment session as the patient breathes naturally. In comparison, gating methods deliver radiation only when the tumor is close to the expected location and pause treatment delivery when the moving tumor is outside of the "treatment window." This potentially lengthens the treatment time and can compromise clinical efficacy.

Additionally, the combination of Synchrony with the Radixact System facilitates the efficient and effective delivery of both hypofractionated and standard radiation therapy, making it easier for clinical teams to provide treatments tailored to meet each individual patient's needs. This functionality directly supports the key priority of value-based healthcare delivery models, such as an alternative payment model, that economically reward treatment quality and efficiency to improve patient outcomes. 

For more information: www.accuray.com

Related Content

he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Lung and respiratory health pioneer paves way for more precise care of complex respiratory conditions
News | Artificial Intelligence | September 25, 2020
September 25, 2020 — VIDA Diagnostics, Inc. announced that it has received 510(k) clearance from the Food and Drug Ad
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s